Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 252, Issue 2, 2014, Pages 331-337

  Moisseiev, Elad ^a   Waisbourd, Michael ^a   Ben Artsi, Elad ^a   Levinger, Eliya ^a   Barak, Adiel ^a   Daniels, Tad ^b   Csaky, Karl ^b   Loewenstein, Anat ^a   Barequet, Irina S ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RETINA FOUNDATION OF THE SOUTHWEST   (United States)

Author keywords

Bevacizumab; Half life; Intravitreal; Pharmacokinetics; Topical

Indexed keywords

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; CATARACT EXTRACTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HALF-LIFE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84894032951     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-013-2495-0     Document Type: Article

References (36)

1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379(9827):1728-1738
2. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S (2011) Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 151:887-895
3. Stewart MW (2012) The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 87:77-88
4. Manzano RPA, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chévez-Barrios P (2007) Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol 91:804-807
5. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383-390
6. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545-2552
7. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI (2008) The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115:33-38
8. Uy HS, Chan PS, Ang RE (2008) Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea 27:70-73
9. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R, Pavan-Langston D, Dana R (2009) Topical bevacizumab in the treatment of corneal neovascularization. Arch Ophthalmol 27:381-389
10. DeStafeno JJ, Kim T (2007) Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 125:834-836
11. Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T (2009) Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 50:4807-4813
12. Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P, Tübingen Bevacizumab Study Group (2008) Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Arch Ophthalmol 86:322-8
13. Dastjerdi MH, Sadrai Z, Saban DR, Zhang Q, Dana R (2001) Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 52:8718-8723
14. Kim MJ, Han ES, Kim JW, Kim TW (2010) Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit. J Ocul Pharmacol Ther 26:49-53
15. Meyer CH, Krohne TU, Holz FG (2012) Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. Acta Ophthalmol 90:68-70
16. Xu HM, Zhou YX, Shi MG (2008) Exploration of three-dimensional biometric measurement of emmetropic adult eye-ball by using magnetic resonance imaging technology. Zhonghua Yan Ke Za Zhi 44:1007-1010
17. Prausnitz MR, Noonan JS (1998) Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 87:1479-1488
18. Brereton HM, Taylor SD, Farrall A, Hocking D, Thiel MA, Tea M, Coster DJ, Williams KA (2005) Influence of format on in vitro penetration of antibody fragments through porcine cornea. Br J Ophthalmol 89:1205-1209
19. Galor A, Yoo SH (2010) Corneal melt while using topical bevacizumab eye drops. Ophthalmic Surg Lasers Imaging 9:1-3
20. Kim TI, Chung JL, Hong JP, Min K, Seo KY, Kim EK (2009) Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 50:4653-4659
21. Gaudreault J, Fei D, Ruzit J, Suboc P, Shiu V (2005) Preclinical pharmacokinetics of ranibizumab after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726-733
22. Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:1375-1382
23. Bock F, Onderka J, Rummelt C, Dietrich T, Bachmann B, Kruse FE, Schlötzer-Schrehardt U, Cursiefen C (2009) Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 50:2095-2102
24. Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335-345
25. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S (2006) Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26:871-876
26. Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Grisanti S, Tübingen Bevacizumab Study Group (2008) Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115:1750-1755
27. Meyer CH, Krohne TU, Holz FG (2011) Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 31:1877-1884
28. Christofordis JB, Carlton MM, Knopp MV, Hinkle GH (2011) PET/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model. Invest Ophthalmol Vis Sci 52:5899-5903
29. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855-859
30. Sinapis CI, Routsias JG, Sinapis AI, Sinapis DI, Agrogiannis GD, Pantopoulou A, Theocharis SE, Baltatzis S, Patsouris E, Perrea D (2011) Pharmacokinetics of intravitreal bevacizumab (Avastin) in rabbits. Clin Ophthalmol 5:697-704
31. Kim H, Fariss RN, Zhang C, Robinson SB, Thill M, Csaky KG (2008) Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci 49:2025-2029
32. Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15:2803-2812
33. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715-725
34. Chin HS, Park TS, Moon YS, Oh JH (2005) Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 25:556-560
35. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB, Miller M (2003) Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110:681-686
36. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF (2007) Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 144:124-126